CASP3 and cholangiocarcinoma: According to in vivo research, allicin 10 and 20 mg/kg was administered, i.e., daily for 4 weeks, and it increased the apoptotic caspases that were produced in Cholangiocarcinoma (CCA) by suppressing STAT3 signalings, such as cleaved caspase-3 and cleaved caspase-9 [66].